title: Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
abstract: OBJECTIVE
  This study investigated the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.
  
  
  METHODS
  In this pilot, multicenter, open-label, randomized study, patients (n = 90) with a known history of T2D treated with diet, oral antidiabetic agents, or low total daily dose of insulin (≤0.4 units/kg/day) were randomized to receive sitagliptin alone or in combination with glargine insulin (glargine) or to a basal bolus insulin regimen (glargine and lispro) plus supplemental (correction) doses of lispro. Major study outcomes included differences in daily blood glucose (BG), frequency of treatment failures (defined as three or more consecutive BG >240 mg/dL or a mean daily BG >240 mg/dL), and hypoglycemia between groups.
  
  
  RESULTS
  Glycemic control improved similarly in all treatment groups. There were no differences in the mean daily BG after the 1st day of treatment (P = 0.23), number of readings within a BG target of 70 and 140 mg/dL (P = 0.53), number of BG readings >200 mg/dL (P = 0.23), and number of treatment failures (P > 0.99). The total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group (both P < 0.001). There were no differences in length of hospital stay (P = 0.78) or in the number of hypoglycemic events between groups (P = 0.86).
  
  
  CONCLUSIONS
  Results of this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D.
authors.affiliation: Corresponding author: Guillermo E. Umpierrez, geumpie@emory.edu.
authors.forename: Guillermo E
authors.initials: GE
authors.lastname: Umpierrez
authors.forename: Roma
authors.initials: R
authors.lastname: Gianchandani
authors.forename: Dawn
authors.initials: D
authors.lastname: Smiley
authors.forename: Sol
authors.initials: S
authors.lastname: Jacobs
authors.forename: David H
authors.initials: DH
authors.lastname: Wesorick
authors.forename: Christopher
authors.initials: C
authors.lastname: Newton
authors.forename: Farnoosh
authors.initials: F
authors.lastname: Farrokhi
authors.forename: Limin
authors.initials: L
authors.lastname: Peng
authors.forename: David
authors.initials: D
authors.lastname: Reyes
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Lathkar-Pradhan
authors.forename: Francisco
authors.initials: F
authors.lastname: Pasquel
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007003:Hypoglycemia / Q000188:drug therapy / Q000209:etiology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007297:Inpatients; D007328:Insulin / Q000627:therapeutic use; D000069036:Insulin Glargine; D061268:Insulin Lispro / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D049528:Insulin, Long-Acting / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D011719:Pyrazines; D014230:Triazoles; D000069036:Insulin Glargine; D000068900:Sitagliptin Phosphate